cpt1

Etomoxir is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a) (IC50=5-20 nM). Etomoxir inhibits fatty acid oxidation by inhibiting CPT-1a, inhibits palmitate oxidation, has an inhibitory effect on adenine nucleotide translocase, and can inhibit macrophage polarization by disrupting CoA homeostasis.

McN3716 is a carnitine palmitoyltransferase I (CPT-1) inhibitor used for researching metabolic diseases.

CU-CPT17e is a potent agonist of TLR(TLR3, TLR8, and TLR9).

Perhexiline maleate is an orally active inhibitor of CPT1 and CPT2, reducing fatty acid metabolism, with IC50 values of 77 μM and 148 μM against rat heart and liver CPT1, respectively.

Etomoxir sodium salt ((R)-Etomoxir sodium salt) is a carnitine palmitoyltransferase 1a (CPT-1a) inhibitor that inhibits fatty acid oxidation (FAO). Etomoxir sodium salt has antitumor activity.

C75 is an inhibitor synthetic fatty-acid synthase (FASN) and inhibits prostate cancer cells PC3 (IC50: 35 μM).C75 increases CPT1 activity and reduces DIO.

Teglicar is a selective and reversible inhibitor of the liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1).

Teglicar (also known as ST1326) is a selective reversible inhibitor of carnitine palmitoyltransferase 1 (L-CPT1), the liver isoform. It reduces ketogenesis and glucose production, decreases gluconeogenesis, and enhances glucose homeostasis.

Perhexiline is an orally active inhibitor of CPT1 and CPT2 that reduces fatty acid metabolism. Perhexiline can cross the blood-brain barrier (BBB) and exhibits anti-tumor activity. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatocytes. Therefore, Perhexiline can be used in cancer and cardiovascular disease research [1] [2] [5].

S-(-)-Etomoxir is an inhibitor of carnitine palmitoyltransferase A (CPT1) -- a molecule required for the oxidation of long-chain acyl CoA esters.

Malonyl CoA serves as a substrate in fatty acid biosynthesis while inhibiting fatty acid oxidation. It also acts as a reversible inhibitor of mitochondrial carnitine palmitoyltransferase (CPT) 1 [1] [2].

4-Hydroxyphenylglyoxylic acid, an active metabolite of the prodrug oxfenicine, functions as an inhibitor of carnitine palmitoyltransferase 1 (CPT1). It effectively inhibits CPT1 in isolated rat liver mitochondria at concentrations of 200 to 1,000 µM and restricts oleate oxidation in isolated rat hepatocytes.